Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 134 | 20% |
| 2020 | 3 | 173 | 23% |
| 2021 | 3 | 135 | 28% |
| 2022 | 2 | 128 | 31% |
| 2023 | 3 | 147 | 34% |
| 2024 | 2 | 134 | 36% |
| 2025 from claims | – | 227 184–267 | 36% |
| 2026 forecast | – | 243 190–305 | 36% |
| 2027 forecast | – | 259 192–343 | 36% |
| 2028 forecast | – | 277 196–382 | 37% |
| 2029 forecast | – | 296 201–424 | 37% |
| 2030 forecast | – | 316 207–468 | 37% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Kansas; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Minnesota | 7 | 358+1.3%/yr | +1.3%/yr | 0.8 | 0% | 500 in 2030+5.8%/yr |
| Illinois | 2 | 357+0.9%/yr | +0.9%/yr | 0.3 | 0% | 740 in 2030+13%/yr |
| Ohio | 1 | 253−4.9%/yr | −4.9%/yr | 0.2 | 0% | 520 in 2030+13%/yr |
| Missouri | 1 | 251−2.1%/yr | −2.1%/yr | 0.4 | 0% | 510 in 2030+12%/yr |
| Wisconsin | 3 | 239−0.5%/yr | −0.5%/yr | 0.4 | 0% | 180 in 2030−5%/yr |
| Michigan | 0 | 228−3.3%/yr | −3.3%/yr | 0.3 | 0% | 370 in 2030+8.4%/yr |
| Indiana | 0 | 141+2.6%/yr | +2.6%/yr | 0.2 | 0% | 190 in 2030+5.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 31 | 2,002−2.5%/yr | −2.5%/yr | 5.20.7× | 34% | 2,170 in 2030+1.4%/yr |
| Tumor & fibroid embolization | 3 | 164+3.8%/yr | +3.8%/yr | 0.40.8× | 65% | 580 in 2030+24%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Minnesota
Exact Sciences leads with 35% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 14 companies reported engagement with Kansas’s surgeons worth $34K in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.